After showing promise in a phase I study, India-based pharma company Zydus Cadila has launched Phase II clinical trials of its COVID-19 vaccine candidate, called ZyCoV-D. Zydus Cadila chairman Pankaj Patel commented, “All the subjects in Phase I clinical trial were closely monitored in a clinical pharmacological unit for 24 hours post-dosing for safety, and for seven days thereafter, and the vaccine was found to be very safe.” Phase II trials will enroll 1,000 volunteers. With over 20 global depots located around the world including Mumbai, India, Yourway is the logistics partner of choice to advance clinical trials successfully.